Matinas Biopharma Holdings earnings were -$20.1M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest MTNB earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$1.7M, down 80.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MTNB reported annual earnings of -$24.3M, with 5.7% growth.
Matinas Biopharma Holdings Earnings Reports & History FAQ
What were Matinas Biopharma Holdings's earnings last quarter?
On MTNB's earnings call on Invalid Date, Matinas Biopharma Holdings (NYSEMKT: MTNB) reported Q1 2025 earnings per share (EPS) of -$0.33, up 75.37% year over year. Total MTNB earnings for the quarter were -$1.66 million. In the same quarter last year, Matinas Biopharma Holdings's earnings per share (EPS) was -$1.34.
Is Matinas Biopharma Holdings profitable or losing money?
As of the last Matinas Biopharma Holdings earnings report, Matinas Biopharma Holdings is currently losing money. Matinas Biopharma Holdings's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$20.08 million, a 13.63% decrease year over year.
What was MTNB's earnings growth in the past year?
As of Matinas Biopharma Holdings's earnings date in Invalid Date, Matinas Biopharma Holdings's earnings has grown year over year. MTNB earnings in the past year totalled -$20.08 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.